NeuroPace is a US-based medical device company developing the RNS® System, an implantable closed-loop neurostimulation platform for the treatment of drug-resistant focal epilepsy. The system combines intracranial EEG sensing with responsive stimulation, continuously monitoring brain activity and delivering targeted electrical pulses when seizure-like patterns are detected. This real-time intervention approach differentiates it from traditional open-loop neuromodulation systems that deliver pre-programmed stimulation regardless of neural state.

The RNS System is implanted directly in or near the seizure focus and connected to leads placed in epileptogenic brain regions. It records long-term neural activity, enabling clinicians to review detailed electrographic data and personalise therapy over time. This dual function, therapeutic intervention and continuous brain monitoring, allows for adaptive optimisation of stimulation parameters based on patient-specific seizure dynamics, improving long-term seizure control outcomes.

NeuroPace received FDA approval for the RNS System and is publicly listed, representing one of the most clinically validated and commercially established examples of closed-loop neuromodulation. Its platform has demonstrated sustained seizure reduction in long-term studies and is widely regarded as a benchmark for next-generation adaptive neurostimulation systems targeting neurological disorders beyond epilepsy.